ArticleBMC cardiovascular disorders2025
Long-term follow-up results of adult atrial septal defect population.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial septal defect (ASD) is a common congenital heart disease (CHD) with significant implications for cardiac function and long-term outcomes in adults. Although ASD often presents in childhood, many cases are diagnosed later in adulthood. Understanding the demographic characteristics, clinical features, and long-term outcomes of adults with ASD is essential for optimizing treatment strategies.
objectivesThis study aimed to evaluate the long-term follow-up outcomes of adult patients with ASD, focusing on survival rates, clinical characteristics, and predictors of mortality.
methodsA retrospective cohort study was conducted, analyzing data from 416 adult ASD patients under follow-up at the Adult Congenital Heart Disease (ACHD) Outpatient Clinic of Istanbul University-Cerrahpasa Institute of Cardiology between 1980 and 2023. Patients were included regardless of treatment status, whether they underwent medical follow-up, percutaneous closure, or surgical closure. Demographic data, clinical characteristics, echocardiographic findings, and hemodynamic parameters were collected. Survival analysis was performed using the Kaplan-Meier method, and Cox regression analysis was used to identify predictors of mortality.
resultsThe study population had a mean age of 48 years, with 71.2% being female. Atrial fibrillation (AF) was present in 13.0% of patients, while pulmonary arterial hypertension (PAH) was observed in 19.7%. Treatment modalities included surgical closure (56.5%), percutaneous closure (15.9%), and medical therapy (27.6%). The median follow-up duration was 3905 days, with a mortality rate of 9.6%. Patients who underwent percutaneous or surgical closure had significantly better survival outcomes compared to those managed with medical therapy alone (p < 0.001). Cox regression analysis identified age, ASD type (non-secundum), and treatment choice (medical therapy) as independent predictors of mortality.
conclusionsThis study underscores the importance of early diagnosis and appropriate treatment in adults with ASD. Percutaneous or surgical closure is associated with improved survival, highlighting the need for timely intervention. Age, ASD type, and treatment choice are crucial predictors of mortality, emphasizing the need for individualized patient management. These findings contribute to the understanding of ASD management and its impact on long-term outcomes in adult patients. Further research should focus on refining risk stratification and optimizing therapeutic strategies for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.